

Non confidential

Investor presentation
13th August 2023

Håkon Sæterøy, CEO & Co-founder

The team

Management team and board with broad experience from life science industry, now strengthening board with international scientific and business team

Management



Erik Christensen

*CMO, co-founder
MD, PhD*



Håkon Sæterøy

*CEO, co-founder
M.Sc Economics and Business*



Line Amundsen

*Laboratory Director
M.Sc Chem*



Board



Ståle Kvitle

*Chairman of the board
Former Johnson & Johnson Director
MBA*



Nicolas Brun-Lie

*Senior Lawyer and private investor
Law degree, Cand Jur*



Thorbjørn Overholt

*Partner, Great Leadership Institute
Master in Political Science*

Inventor & Scientific Advisor



Dr. Tormod Fladby

*Head of Neuroscience Dept.
Akershus University Hospital
Professor, Dr Med*

June 2023 three active advisors were elected new Board Members:

- **Professor Ole Petter Ottersen, MD, PhD (Neuroscience).** *Former President of University of Oslo (2009-2017) and President of Karolinska Institutet (2017-2023).*
- **Laura Chirica, M.Sc, PhD.** *CEO of Cellevate AB. Former CCO of Immunovia AB, former VP Sales & Marketing of Svar Life Science AB, Global Marketing Program Director of DAKO A/S and Global Product Manager GE Healthcare.*
- **Marie S. Buchmann, MD, PhD.** *Medical Director with Fürst medical laboratory 2000-2023.*



Our Solution

CE marked Biomarkers enabling precision medicine


“Early days” and very large unmet need for biomarkers within neurodegenerative diseases for pharma as well as clinical diagnostics

- Identifying patients with active neurodegeneration earlier
- Predicting the likelihood that a therapy may be effective in certain individuals by identifying subgroups
- Predicting risk groups with regards to adverse effects to ensure safety

Enabling pharma researchers and clinicians to provide the right treatment to the right patients at the right time

The new Alzheimer's paradigm: The 2025 AD patient journey

New blood test diagnostics for easy and effective diagnostics in early phase and new pharma treatments available



We are developing a suite of unique fluid biomarkers for dementia

Our proprietary platform technology with potential to move into precision medicine with ARIA-project



Biomarker Selection



Antibody Development



Prototype Assay



Analytical Validation



Clinical Validation

Alzheimer's disease



Parkinson's disease



*RuO = Research Use Only (use of test as biomarker in clinical trials/research segment)

4 main strategic elements makes 4 company projects 2023-25

Uniquely positioned in neuroscience for a large global market with strong need for dementia-solutions

1 PreADx project

CE-marked immunoassays from VERDAD project need further clinical validation. AI-Mind, JPND and DDI network. Latest news: To be applied on saliva samples.

2 ARIA project

RCN grant for biomarker system applicable for pipeline of AD immunotherapies. High potential within precision medicine

3 PrePDx project

RCN grant for developing blood-based diagnostics for Parkinson's disease. Very high unmet clinical need, industry interest verified.



Service Lab
«Core facility»

4 ISO certified Service laboratory

- ✓ Several thousands of blood samples to be analysed in AI-Mind project
- ✓ PrePDx project and other internal tasks
- ✓ Preparing for IVD Regulative 2024
- ✓ Service laboratory as an income source covering basic costs and salaries

* Previously Funded by




PreADx platform consists of two CE-marked immunoassay kits and monocyte isolation kits and procedures



Ab 20-X assay demonstrates robustness and improved diagnostic performance characteristics vs X-34, incl. stronger early-phase signals





Ab X-34 demonstrates high clinical significance related to CNS amyloid pathology, and will be used in the ARIA detection project



Recap of our technology


Intracellular measurement of biomarkers, with a new monocyte isolation method using paramagnetic beads



Recap of our basic technology

Intracellular measurement of biomarkers, with a new monocyte isolation method using paramagnetic beads


Proprietary antibodies



Market traction: Building PreADx clinical utility documentation strategically

Leveraging European collaborations and 3d party clinical studies while building KOL-relations at specialist clinics

- Build
- Expand
- Launch





US launch of new AD immunotherapies has put the spotlight on ARIA

ARIA = Amyloid related imaging abnormalities

AD Immunotherapy pipeline

- All immunotherapy treatments that target amyloid plaque have an associated ARIA-risk for patients
- Big Pharma players with FDA Breakthrough Drug Designations in 2021, potential launch from 2023 onwards pending FDA approval



ARIA: Serious Adverse Effect

- ARIA is serious swelling/bleeding of the brain in patients as a response to amyloid-targeting immunotherapy
- Up to 40% of patients eligible for treatment at risk for ARIA
- Currently, no tools available for determining a patient's ARIA risk

CE-marked PreADx X-34 test to be used in a new category within AD diagnostics – market traction AI-Mind partner & global IVD player




“It is not clear that the abnormalities (ARIA) can be properly monitored and managed in clinical practice”



The ARIA Risk Test: Predicting which patients are at risk for ARIA

Application of CE marked test PreADx monocyte X-34 to measure maximal Abeta clearance capacity


Hi!
My name is **MARIA**
and I have AD.



RESULT


«I recommend immunotherapy with donanemab for MARIA»

*Sincerely,
Dr. Smith*



Amyloid-targeting immunotherapy adversely impact pericyte activity



Defective pericytes clear fewer A β 34-fragments, and less of this biomarker will transfer to the blood



- A defective pericyte apparatus will hamper normal clearance and lead to increased A β flow due to the amyloid-targeting immunotherapy effect
 - A β 1-40 will be cleared by pericytes until A β 1-42 accumulates and destroys pericytes
- This increased flow causes leakage of cells and fluid into the CNS as seen in ARIA
- Less A β 34 fragments are detected by PreADx X-34 in blood
- PreADx X-34 as a surrogate marker for pericyte viability

The challenge: Parkinson's Disease

- A neurodegenerative disease; motor symptoms and eventually cognitive defects.
 - A massive neurodegeneration upon initial clinical diagnosis
- The protein alpha Synuclein (α -Syn), central in neurotransmitter release, is widely considered to be a biomarker for PD.
 - Due to extensive Post Translational Modifications (PTMs), Total α -Syn in plasma and CNS has failed as a clinically relevant biomarker.
- Early PD detection is needed to pave the way for major advances in disease modifying therapies




Currently no early, specific blood-based test exists



Photo: Anders M. Leines

Our solution: Intracellular measurement of α -Syn fragments



- The innate immune system plays a pivotal role in clearance of the toxic proteins in neurodegenerative diseases
- Our hypothesis is that the α -Syn clearance efficiency and cleavage pattern in monocytes of PD patients deviates from healthy persons.
- Monocytes are isolated from a blood sample followed by lysis. Specific antibodies will bind to α -Syn peptides, and their concentration are measured by an immunoassay.

Collaborators Parkinson's project

Academic



AKERSHUS UNIVERSITY HOSPITAL



DDI

Dementia Disease Initiative



Oslo University Hospital



UiO : University of Oslo



TURKU BIOSCIENCE



Nasjonalt kompetansetjeneste for bevegelsesforstyrrelser

Corporate



GE HealthCare




Bioventix



Mathias Toft, MD, PhD
Head of Neuroscience Dept
Oslo University Hospital
Professor



Tormod Fladby, MD, PhD
Head of Neuroscience Dept
Akershus University Hospital
Professor



Lasse Pihlstrøm, MD, PhD
Head of research, Neuroscience Dept
Oslo University Hospital



Krisztina K. Johansen, MD, PhD
Akershus University Hospital

State of the art neurolab as a core facility

Lab and Development Capabilities

- Assay development and method transfer
- Validation
- Biomarker and lab services
- IVD kit production
- QMS according to ISO13485
- Partnership with antibody provider
- Development platforms

- SIMOA, ELISA, MSD, MS

Fluid biomarkers that enable precision medicine

- Large unmet need for biomarkers within neurodegenerative diseases for pharma as well as clinical diagnostics




- Identify patients for new treatment opportunities
- Monitor the safety of a therapy
- Determine if a treatment is having the desired effect on the body
- Predict patients who might respond better to a drug from a safety or efficacy perspective
- Potentially enable time and cost savings in clinical trials

Enabling pharma industry and clinicians to target the right treatments to the right patients at the right time

Pre Neurolab

Service Laboratory for market traction



Market Strategy for PreADx Biomarkers

PreADx Biomarkers aimed at the pharma as well as diagnostics segments



PreADx

Diagnostic Platform Providers

Antibodies

Assay

Out licensing deal

Earlier detection of AD patients

Pharma Partners

Co-development through inclusion in clinical trials

Stratification, Safety and efficacy applications

Laboratory services

Diagnostic testing within neurodegenerative diseases

PreDX CE-IVD kits as base

Early proof of concept and generation of clinical data

Latest project: Funnelling dementia test based on saliva

Extract from new grant application Research Council of Norway June 2023:

“For the first time in 20 years new Alzheimer’s disease (AD) drugs are entering the market.

- **The underlying innovation of the present project is to develop a *funnelling diagnostic test* that is suitable for screening of individuals who could be eligible for these new immunotherapies.**
- **In addition, the novel test would be ideal as a *home-to-lab based test* grounded on a new analytic system for detecting disease specific biomarkers in saliva.**

A bio resource such as saliva will allow individuals to self-collect and send samples to centralized medical laboratories for clinical investigation under ambient conditions, a much more simplistic pre-analytical alternative than currently available alternatives.

- **The patent protected innovation has the potential to assist in identifying individuals in the long pre-symptomatic phase of AD, and who might benefit the most from clinical/therapeutic interventions.”**

Technology potential recognized by US life science analysts

Recently PreDx has entered into an agreement with the US based financial services firm BTIG to provide strategic and capital markets advisory services

The BTIG analyst wrote:

"I am very excited about all the diagnostic/monitoring/personalized medicine opportunities in neurodegenerative diseases, and I think it's a great time to be a key player in the space right now."